| Literature DB >> 29335418 |
Mariko Sasaki1,2,3, Sei Harada4, Yumiko Kawasaki5, Miki Watanabe6, Hidemi Ito7, Hideo Tanaka8, Ayano Takeuchi4, Kazuo Tsubota1, Toru Takebayashi4, Yuji Nishiwaki9, Ryo Kawasaki10.
Abstract
The Tsuruoka Metabolomics Cohort Study included subjects aged 35-74 years from participants in annual health check-up programs in Tsuruoka, Japan. The gender-specific associations of early age-related macular degeneration (AMD) with systemic and genetic factors was assessed cross-sectionally. Of these, 3,988 subjects had fundus photographs of sufficient quality, and early AMD was present in 12.3% and 10.3% of men and women, respectively. In men, higher levels of high-density lipoprotein cholesterol and lower levels of triglycerides were associated with increased odds of having early AMD after adjusting for potential risk factors (for each 1 mmol/L increase, odds ratio [OR]: 1.61 and 0.78, 95% confidence interval [CI]: 1.17-2.23 and 0.64-0.96, respectively). In women, higher levels of total cholesterol and low-density lipoprotein cholesterol were associated with increased risk of having early AMD (OR: 1.21 and 1.26, 95% CI: 1.01-1.44 and 1.03-1.53, respectively). Sub-analysis demonstrated that women with ARMS2 A69S polymorphisms had a stronger risk for early AMD (OR: 3.25, 95% CI: 2.10-5.04) than men (OR: 1.65, 95% CI: 1.02-2.69). Differential associations of early AMD with both systemic and genetic factors by sex were demonstrated in a Japanese cohort, which suggests that disease process of early AMD could be different by sex.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29335418 PMCID: PMC5768785 DOI: 10.1038/s41598-017-18487-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart describing subject selection from participants of the Tsuruoka Metabolomics Cohort Study.
Age-specific prevalence of early and late AMD according to sex.
| Large drusen | Pigmentary abnormalities | Early AMD | Late AMD | Any AMD | |
|---|---|---|---|---|---|
|
| |||||
| −49, n = 160 | 10 (6.3) | 1 (0.6) | 11 (6.9) | 0 (0) | 11 (6.9) |
| 50–59, n = 385 | 32 (8.3) | 0 (0) | 32 (8.3) | 0 (0) | 32 (8.3) |
| 60–69, n = 955 | 119 (12.5) | 9 (0.9) | 121 (12.7) | 1 (0.1) | 122 (12.8) |
| 70–74, n = 315 | 60 (19.0) | 2 (0.6) | 60 (19.0) | 1 (0.3) | 61 (19.4) |
| Total, n = 1815 | 221 (12.2) | 12 (0.7) | 224 (12.3) | 2 (0.1) | 226 (12.5) |
|
| |||||
| −49, n = 150 | 2 (1.3) | 0 (0) | 2 (1.3) | 0 (0) | 2 (1.3) |
| 50–59, n = 409 | 19 (4.6) | 0 (0) | 19 (4.6) | 0 (0) | 19 (4.6) |
| 60–69, n = 1217 | 130 (10.7) | 2 (0.2) | 130 (10.7) | 0 (0) | 130 (10.7) |
| 70–74, n = 397 | 72 (18.1) | 2 (0.5) | 72 (18.1) | 0 (0) | 72 (18.1) |
| Total, n = 2173 | 223 (10.3) | 4 (0.2) | 223 (10.3) | 0 (0) | 223 (10.3) |
|
| |||||
| −49, n = 310 | 12 (3.9) | 1 (0.3) | 13 (4.2) | 0 (0) | 13 (4.2) |
| 50–59, n = 794 | 51 (6.4) | 0 (0) | 51 (6.4) | 0 (0) | 51 (6.4) |
| 60–69, n = 2172 | 249 (11.5) | 11 (0.5) | 251 (11.6) | 1 (0.05) | 252 (11.6) |
| 70–74, n = 712 | 132 (18.5) | 4 (0.6) | 132 (18.5) | 1 (0.1) | 113 (18.7) |
| Total, n = 3988 | 444 (11.1) | 16 (0.4) | 447 (11.2) | 2 (0.05) | 449 (11.3) |
Basic characteristics according to sex.
| Variables | Men | Women | ||||
|---|---|---|---|---|---|---|
| Early AMD, n = 224 | Control, n = 1591 | P value | Early AMD, n = 223 | Control, n = 1950 | P value | |
| No. (%) or Mean ± SD | No. (%) or Mean ± SD | No. (%) or Mean ± SD | No. (%) or Mean ± SD | |||
| Age, y | 64.5 ± 7.1 | 61.7 ± 8.0 |
| 66.2 ± 5.3 | 62.2 ± 7.4 |
|
| BMI, kg/m2 | 23.4 ± 2.8 | 23.7 ± 3.1 | 0.31 | 23.4 ± 3.3 | 23.0 ± 3.4 |
|
| Smoking history | ||||||
| Current/past | 181 (80.8) | 1290 (81.1) | 0.93 | 12 (5.4) | 198 (10.1) |
|
| Never | 43 (19.2) | 301 (18.9) | 211 (94.6) | 1752 (89.9) | ||
| Hypertension | 121 (54.0) | 854 (53.7) | 0.92 | 127 (57.0) | 892 (45.7) |
|
| Dyslipidemia | 95 (42.4) | 800 (50.3) |
| 143 (64.1) | 1055 (54.1) |
|
| Diabetes | 22 (9.8) | 218 (13.7) | 0.11 | 16 (7.2) | 139 (7.1) | 0.98 |
| Antihypertension medication | 83 (37.1) | 515 (32.4) | 0.16 | 78 (35.0) | 574 (29.4) | 0.087 |
| Lipid-lowering medication | 28 (12.5) | 223 (14.0) | 0.54 | 77 (34.5) | 500 (25.6) |
|
| Total cholesterol, mmol/L | 202.2 ± 31.5 | 205.3 ± 34.7 | 0.27 | 217.9 ± 32.6 | 214.7 ± 32.2 | 0.14 |
| HDL cholesterol, mmol/L | 67.3 ± 16.1 | 63.4 ± 17.0 |
| 71.8 ± 16.3 | 72.2 ± 16.6 | 0.71 |
| LDL cholesterol, mmol/L | 113.0 ± 29.3 | 116.4 ± 30.9 | 0.17 | 127.2 ± 31.1 | 123.6 ± 29.2 | 0.077 |
| Triglyceride, mmol/L | 110.4 ± 60.6 | 131.0 ± 97.8 |
| 94.3 ± 41.5 | 94.9 ± 46.5 | 0.82 |
Significant values are in bold.
Logistic regression analysis of factors for early AMD according to sex.
| Variables | Men | Women | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | |||||||||
| Odds | 95% CI | P-value | Odds | 95% CI | P-value | Odds | 95% CI | P-value | Odds | 95% CI | P-value | |
| Age, per 1 year |
|
|
|
|
|
|
|
|
|
|
|
|
| BMI, per 1 kg/m2 | 0.98 | 0.93–1.03 | 0.41 | 1.00 | 0.95–1.05 | 0.93 | 0.99 | 0.94–1.04 | 0.15 | 1.03 | 0.981–1.07 | 0.24 |
| Smoking history, | 1.09 | 0.76–1.56 | 0.65 | 1.13 | 0.78–1.62 | 0.53 | 0.85 | 0.46–1.58 | 0.61 | 0.84 | 0.45–1.56 | 0.58 |
| Current/past vs Never | ||||||||||||
| Hypertension | 0.88 | 0.66–1.17 | 0.37 | 0.93 | 0.69–1.25 | 0.59 | 1.21 | 0.90–1.61 | 0.20 | 1.15 | 0.85–1.545 | 0.37 |
| Dyslipidemia | 0.77 | 0.58–1.27 | 0.075 | 0.80 | 0.60–1.08 | 0.14 | 1.31 | 0.98–1.75 | 0.071 | 1.28 | 0.95–1.71 | 0.10 |
| Diabetes | 0.63 | 0.39–1.00 | 0.050 | 0.66 | 0.41–1.06 | 0.080 | 0.79 | 0.46–1.36 | 0.40 | 0.73 | 0.42–1.26 | 0.25 |
| Total cholesterol, per 1 mmol/L | 0.95 | 0.81–1.12 | 0.57 | 0.95 | 0.80–1.12 | 0.50 | 1.17 | 0.98–1.38 | 0.078 |
|
|
|
| HDL cholesterol, per 1 mmol/L |
|
|
|
|
|
| 1.01 | 0.73–1.41 | 0.94 | 1.08 | 0.76–1.53 | 0.64 |
| LDL cholesterol, per 1 mmol/L | 0.91 | 0.76–1.09 | 0.28 | 0.89 | 0.74–1.07 | 0.22 |
|
|
|
|
|
|
| Triglyceride, per 1 mmol/L |
|
|
|
|
|
| 0.94 | 0.71–1.24 | 0.64 | 0.90 | 0.67–1.21 | 0.44 |
HDL: high-density lipoprotein, LDL: low-density lipoprotein; Significant values are in bold. Model 1: Adjusted for age. Model 2: For serum lipid: adjusted for age, BMI, smoking history, hypertension, diabetes, and lipid-lowering medication. For the others: adjusted for age, BMI, smoking history, hypertension, dyslipidemia, and diabetes.
Genetic risk for early AMD according to sex.
| Genotype | Prevalence (%) | Men | Prevalence (%) | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control, n = 1236 | Early AMD, n = 174 | Control, n = 1548 | Early AMD, n = 181 | |||||||
| No. (%) | No. (%) | Odds (95% CI) | P-value | No. (%) | No. (%) | Odds (95% CI) | P-value | |||
| rs10490924/ARMS2 | ||||||||||
| GG | 10.7 | 500 (40.5) | 60 (34.5) | 1 (reference) | 7.4 | 604 (39.0) | 48 (26.5) | 1 (reference) | ||
| TG | 12.6 | 589 (47.7) | 85 (48.8) | 1.21 (0.85–1.72) | 0.716 | 10.0 | 753 (48.6) | 84 (46.4) | 1.38 (0.95–2.01) | 0.0979 |
| TT | 16.5 | 147 (11.9) | 29 (16.7) | 1.65 (1.02–2.69) | 0.069 | 20.4 | 191 (12.3) | 49 (27.1) |
|
|
| rs800292/CFH I62V | ||||||||||
| CC | 9.9 | 456 (36.9) | 50 (28.7) | 1 (reference) | 8.5 | 559 (36.1) | 52 (28.7) | 1 (reference) | ||
| CT | 13.8 | 582 (47.1) | 93 (53.5) | 1.45 (1.01–2.1) | 0.2425 | 9.8 | 760 (49.1) | 83 (45.9) | 1.12 (0.77–1.61) | 0.126 |
| TT | 13.5 | 198 (16.0) | 31 (17.8) | 1.43 (0.88–2.32) | 0.4299 | 16.7 | 229 (14.8) | 46 (25.4) |
|
|
Adjusted for age; Significant values are in bold.